Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-01

Study Completion Date

2008-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer

NCT00242190

Pancreatic Neoplasms

COMPLETED PHASE1/PHASE2

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer

NCT00026403

Pancreatic Cancer

COMPLETED PHASE2

Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer

NCT02984501

Pancreatic Cancer

COMPLETED PHASE2

Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

NCT00335543

Pancreatic Cancer

COMPLETED PHASE2

Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00275119

Pancreatic Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Association of gemcitabine, oxaliplatin and radiotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease
* WHO performance status of 0 or 1
* Complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed
* Maximum delay after surgery: 8 weeks
* No previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ
* Adequate bon marrow reserve
* No previous chemotherapy or radiotherapy
* Expected survival \> 6 months

Exclusion Criteria

* Active infection
* Metastatic disease
* Inadequate liver function after derivative surgery
* Inadequate renal function
* Pregnancy, breast feeding
* Use of any other investigational agent in the month before enrollment
* Patients with grade 2 or more neuropathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No